Health care company Bayer said on Friday that it has exercised its option to obtain the exclusive licensing rights for the global development and commercialisation of Vitrakvi and BAY 2731954 under the change-in-control clause collaboration agreement with Loxo Oncology.
Both the Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) compounds are being developed globally for the treatment of adult and paediatric patients with advanced solid tumours harboring NTRK gene fusions, added Bayer.
TRK fusion cancer occurs when an NTRK gene fuses with another unrelated gene, producing an altered TRK protein. The altered protein, or TRK fusion protein, becomes constitutively active or overexpressed, triggering a signaling cascade. These TRK fusion proteins act as oncogenic drivers promoting cell growth and survival, leading to TRK fusion cancer, including lung, thyroid, GI cancers (colon, cholangiocarcinoma, pancreatic and appendiceal), sarcoma, CNS cancers (glioma and glioblastoma), salivary gland cancers (mammary analogue secretory carcinoma) and paediatric cancers (infantile fibrosarcoma and soft tissue sarcoma), disclosed the company.
Following this exercise, the joint co-promotion agreement in the US between Bayer and Loxo Oncology is being converted to full commercialisation in the US by Bayer and the sharing of commercial costs and profits on a 50/50 basis for the US market will be replaced by royalties to be paid by Bayer. Bayer will continue to pay royalties on future net sales outside the US .The option was triggered by the acquisition of Loxo Oncology by Eli Lilly and Company.
In conjunction with Bayer's exercise of the option, certain licenses granted by Loxo Oncology to Bayer will become exclusive following anti-trust clearance in the US.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval